Aprotinin in the management of life-threatening bleeding during extracorporeal life support

Abstract

Contact with the synthetic surfaces of an extracorporeal circuit induces alterations in vascular components, derangements of the coagulation cascade and a systemic inflammatory response. Aprotinin reduces intraoperative and postoperative bleeding in adults undergoing cardiopulmonary bypass; however, trials in children have not had similar favorable results. While there have been some anecdotal reports, there have been no prospective clinical trials exploring the utility of aprotinin in the prevention of or as a therapy for bleeding while on extracorporeal life support (ECLS). We present a case series on our experience utilizing aprotinin for the treatment of life-threatening bleeding during ECLS. The combination of a loading dose followed by a continuous infusion resulted in significant reduction in blood loss and blood product utilization. This suggests that aprotinin may have clinical efficacy in the management of massive blood loss while on ECLS; however, larger controlled trials will be essential to determine the efficacy and appropriate dosing regimens before widespread use in ECLS can be advocated.

Get full access to this article

View all access options for this article.

References

Westaby S. Aprotinin in perspective . Ann Thorac Surg 1993; 55: 1033-1041 .

Wildevuur C , Eijsman L , Roozendaal K et al. Platelet preservation during cardiopulmonary bypass with aprotinin . Eur J Cardio-thorac Surg 1989; 3: 533-538 .

Shigeta O , Kojima H , Jikuya T et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass . Circulation 1997; 96: 569-574 .

van Oeveren W , Harder M , Roozendaal K , et al. Aprotinin protects platelets against the initial effects of cardiopulmonary bypass . J Thorac Cardiovasc Surg 1990; 99: 788-797 .

Huang H , Ding W , Su Z , Zhang W. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery . J Thorac Cardiovasc Surg 1993; 106: 11-18 .

van Oeveren W , Eijsman L , Roozendaal K et al. Platelet preservation by aprotinin during cardiopulmonary bypass . Lancet 1988; 11: 644-644 .

Boldt J , Knothe C , Zickmann B et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations . J Thorac Cardiovasc Surg 1993; 105: 705-711 .

Davies M , Allen A , Kort H et al. Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations . Ann Thorac Surg 1997; 63: 497-503 .

Jaquiss R , Huddleston C , Spray T. Use of aprotinin in pediatric lung transplantation . J Heart Lung Transplant 1995; 14: 302-307 .

10.

Boldt J , Knothe C , Zickmann B et al. Aprotinin in pediatric cardiac operations: platelet function, blood loss, and use of homologous blood . Ann Thorac Surg 1993; 55: 1460-1466 .

11.

Plotz F , van Oeveren W , Bartlett R et al. Blood activation during neonatal extracorporeal life support . J Thorac Cardiovasc Surg 1993; 105: 823-832 .

12.

Wachtfogel Y , Kucich U , Hack C et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion . J Thorac Cardiovasc Surg 1993; 106: 1-10 .

13.

Brunet F , Mira J , Belghith M et al. Effects of aprotinin on hemorrhagic complications in ARDS patients during prolonged extracorporeal CO2removal . Int Care Med 1992; 18: 364-367 .

14.

Mössinger H , Dietrich W. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage . Ann Thorac Surg 1998; 65: S45-S51 .